Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06021340

What To-be-discard Biomaterials From ART Cycles Can Tell us About the Treatment Cycle Outcome?

Status
Recruiting
Phase
Study type
Observational
Enrollment
50 (estimated)
Sponsor
Chinese University of Hong Kong · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers

Summary

Various to-be-discard material from IVF treatment cycle will be collect and examined, aiming to identify potential reasons of successful outcome or cycle failure.

Detailed description

Usually around 2/3 of IVF material will be discarded at the end of each treatment cycle, including immature oocytes, abnormal fertilized zygotes, poor grading embryos, spent culture medium, etc. Next generation sequencing will be performed for DNA / RNA analysis including the length and the quantity, RNA-seq will be applied for transcriptome profiling, and protein profile will be investigated in a pool sample. By applying various diagnostic tools against those to-be-discard biomaterials, we aim to identify potential underlying reasons of indicating either for an IVF failure or a successful cycle, and try to develop a non-invasive testing method for embryo quality check; better detection of the embryo implantation potential and eventually further increase the IVF clinical outcome.

Conditions

Timeline

Start date
2023-07-04
Primary completion
2026-12-01
Completion
2027-06-01
First posted
2023-09-01
Last updated
2023-09-01

Locations

1 site across 1 country: Hong Kong

Source: ClinicalTrials.gov record NCT06021340. Inclusion in this directory is not an endorsement.